USPTO Examiner VAJDA KRISTIN ANN - Art Unit 1622

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18988163SYNTHESIS OF KRAS G12C INHIBITOR COMPOUNDDecember 2024June 2025Abandon610NoNo
18988090SYNTHESIS OF KRAS G12C INHIBITOR COMPOUNDDecember 2024June 2025Abandon610NoNo
18913645PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFOctober 2024April 2025Allow611NoNo
18805702Diagnosis and Treatment of VitiligoAugust 2024May 2025Allow911YesNo
18792836METHODS OF TREATING BRAIN DISORDERSAugust 2024May 2025Allow911NoNo
18776040PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFJuly 2024January 2025Allow620NoNo
18743233PHARMACEUTICAL COMBINATIONS FOR TREATING CANCERJune 2024May 2025Allow1110NoNo
18744484NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONSJune 2024May 2025Allow1110NoNo
18743475SARS-COV2 MAIN PROTEASE INHIBITORSJune 2024April 2025Allow1110NoNo
18734105PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFJune 2024December 2024Allow611NoNo
18675584PIKfyve InhibitorsMay 2024June 2025Abandon1210NoNo
18596586NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETYMarch 2024January 2025Allow1010NoNo
18584272VANADIUM ALKYLIDENE COMPLEX, SYNTHESIS AND USE THEREOFFebruary 2024September 2024Allow611NoNo
18582218IRAK DEGRADERS AND USES THEREOFFebruary 2024October 2024Allow800NoNo
18430056C7 SUBSTITUTED OXYSTEROLS AND METHODS OF USE THEREOFFebruary 2024February 2025Allow1210YesNo
18393778SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOFDecember 2023October 2024Allow1010NoNo
18530758AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORSDecember 2023December 2024Abandon1310NoNo
18496049NEW COMPOUNDS AND METHODS OF THEIR MANUFACTURINGOctober 2023August 2024Allow1001YesNo
18491524METHOD OF TREATING CONDITIONS RELATED TO THE PGI2 RECEPTOROctober 2023January 2025Allow1510NoNo
18379576Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses ThereofOctober 2023April 2025Abandon1811NoNo
18485093COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERSOctober 2023October 2024Abandon1310NoNo
18480442PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOROctober 2023August 2024Allow1010NoNo
18372210Lithium Conducting Carbon Phosphonitrides from Substituted CyanophosphineSeptember 2023April 2025Allow1910NoNo
18371722NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEXSeptember 2023August 2024Allow1110NoNo
18370186DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENTSeptember 2023March 2025Allow1811NoNo
18244659HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOFSeptember 2023December 2024Allow1510NoNo
18241583COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTHSeptember 2023October 2024Allow1310NoNo
18236532THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTIONAugust 2023July 2024Allow1110NoNo
18354163COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESISJuly 2023September 2024Allow1410NoNo
18212375HYDROXYNORKETAMINE FOR THE USE IN THE TREATMENT OF DEPRESSIONJune 2023October 2024Allow1611NoNo
18328267Process For Preparing Aminopyrimidine DerivativesJune 2023August 2024Allow1520NoNo
18328350PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFJune 2023September 2023Allow310YesNo
18200410Methods of Modifying Neuronal Function by Changing Intracellular Magnesium LevelsMay 2023December 2024Abandon1801NoNo
18196128ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERSMay 2023July 2024Allow1411NoNo
18309992ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICESMay 2023November 2024Allow1811NoNo
18305911IRAK DEGRADERS AND USES THEREOFApril 2023November 2023Allow600NoNo
18043178SURFACTANTSFebruary 2023May 2025Allow2610NoNo
18113047Non-distillative Process for Manufacturing High Purity AmphetaminesFebruary 2023December 2024Allow2211NoNo
18018393Indole Alkaloid With Fungicidal EffectJanuary 2023July 2025Allow2900NoNo
18093569CRYSTALLINE FORMS OF ERAVACYCLINEJanuary 2023December 2024Allow2310NoNo
18004313MANUFACTURE OF COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2January 2023June 2025Allow2900NoNo
17904464NOVEL PHOTOSENSITIZERDecember 2022June 2025Allow3400NoNo
18075386ANALOGS OF CYCLOBENZAPRINE AND AMITRYPTILENEDecember 2022July 2024Allow1921YesNo
18072154ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAMENovember 2022November 2024Allow2420NoYes
17984011COMPOSITIONS AND METHODS TO REDUCE PATHOGENESISNovember 2022December 2024Abandon2501NoNo
17997597METHODS OF PREPARING SYNTHETIC CANNABICHROMENE AND CANNABICITRAN AND DERIVATIVES THEREOFOctober 2022December 2024Allow2500NoNo
17997483SPIROUREA DERIVATIVESOctober 2022December 2024Allow2600NoNo
17961020Phosphonium Compound, Reagent Kit for Derivatization, Mass Spectrometric Method, and Method for Producing Phosphonium CompoundOctober 2022January 2025Allow2811YesNo
17906132Compounds and Method of Treating COVID-19September 2022April 2025Allow3100NoNo
17631114WDR5-MYC INHIBITORSAugust 2022April 2025Allow3910NoNo
17781777PROCESS FOR SYNTHESIS OF A 2-(5-ISOXAZOLYL)-PHENOLJune 2022January 2025Allow3100NoNo
17756737MACROCYCLES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERSJune 2022May 2025Allow3610NoNo
17780161HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASEMay 2022March 2025Allow3400NoNo
17776950IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUNDMay 2022June 2025Allow3810YesNo
17776948IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUNDMay 2022June 2025Allow3810YesNo
17775863AMORPHOUS PHARMACEUTICAL COMPOSITIONS OF ABIRATERONE ACETATEMay 2022June 2025Allow3710NoNo
17773135OXADIAZOLINE COMPOUND OR SALTS THEREOF, AGRICULTURAL AND HORTICULTURAL FUNGICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAMEApril 2022April 2025Allow3610NoNo
17773136PHARMACEUTICAL COMPOUNDSApril 2022June 2025Allow3810NoNo
17770083PROCESS FOR PREPARATION OF THIOPHOSPHORYL CHLORIDE AND ACEPHATEApril 2022January 2025Allow3311YesNo
17719412PULMONARY HYPERTENSION TREATMENTApril 2022November 2024Allow3111NoNo
17768354PHOSPHORAMIDITE ACTIVATORApril 2022September 2024Allow2900NoNo
17767034SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDSApril 2022June 2025Allow3810NoNo
17762793ALDOKETO REDUCTASE INHIBITORS AND USES THEREOFMarch 2022April 2025Allow3710NoNo
17697089Method of Regulating Immunity in the IntestinesMarch 2022October 2024Allow3121NoNo
17642092HETEROBICYCLIC CARBOXAMIDES AND USES THEREOFMarch 2022June 2025Allow3910NoNo
17640697OIL LIQUID FUNGICIDAL COMPOSITIONSMarch 2022June 2025Allow4010NoNo
17636331HETEROCYCLIC THR-B RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREFORFebruary 2022March 2025Allow3710YesNo
17635491CRYSTALLINE FORM OF L-GLUFOSINATE AMMONIUM SALT AND PROCESS FOR PRODUCTION THEREOFFebruary 2022December 2024Allow3411YesNo
17635462Preparation Method for Oxazepine CompoundFebruary 2022May 2025Allow3910NoNo
17634174COMPOUNDS SUITABLE FOR THE TREATMENT AND PROPHYLAXIS OF MUSCLE WASTING AND OTHER CONDITIONSFebruary 2022February 2025Allow3600NoNo
17629955UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTORJanuary 2022January 2025Allow3600YesNo
17627915TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORSJanuary 2022February 2025Allow3700NoNo
17563913COMPOUNDS AND METHODS FOR INHIBITING JAKDecember 2021January 2025Allow3710NoNo
17621705HIGH YIELD, ECO-FRIENDLY RECYCLING METHOD OF POLYLACTIC ACID USING SUPERCRITICAL OR DENSE GAS CARBON DIOXIDEDecember 2021November 2024Allow3500NoNo
17619739NEW COMPOSITION CONTAINING BRANCHED-CHAIN AMINO ACIDSDecember 2021November 2024Allow3510NoNo
17611977OXADIAZOLE COMPOUNDS OR SALTS THEREOF, AGROHORTICULTURAL FUNGICIDES CONTAINING THE COMPOUNDS, AND METHODS OF USING THE SAMENovember 2021August 2024Allow3300NoNo
17611093CANNABINOIDS AND USES THEREOFNovember 2021December 2024Allow3701NoNo
175097695,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one Compounds and Methods of UseOctober 2021August 2024Allow3300NoNo
17605111INHIBITORS OF CYCLIN-DEPENDENT KINASESOctober 2021February 2025Abandon4010NoNo
17602803INHIBITORS OF TRPC6October 2021August 2024Allow3400NoNo
17602758PIPERAZINE AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINEOctober 2021December 2024Allow3810NoNo
17599391Pharmaceutical Combination Formulations Comprising Tizanidine, Resveratrol and PiperineSeptember 2021May 2025Abandon4301NoNo
17599341ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDSSeptember 2021October 2024Allow3610YesNo
17598569PANTETHENOYLCYSTEINE DERIVATIVES AND USES THEREOFSeptember 2021November 2024Allow3811NoNo
17598271TREATMENT OF HIDRADENITIS SUPPURATIVA WITH TAPINAROF COMPOSITIONSSeptember 2021April 2025Abandon4301NoNo
17442022METHODS FOR TREATING COLORECTAL CANCERSeptember 2021April 2025Abandon4201NoNo
17437519COMPOUNDS HAVING EXCITED STATE INTRAMOLECULAR PROTON TRANSFER (ESIPT) CHARACTER FOR USE IN TREATING AND/OR PREVENTING SUNBURN AND/OR PREVENTING U.V. DAMAGESeptember 2021December 2024Allow3901NoNo
17593110POLYMORPHS AND COCRYSTALS OF A CARDIAC TROPONIN ACTIVATORSeptember 2021June 2024Allow3300NoNo
17436231USE OF CAPRYLIC AND CAPRIC TRIGLYCERIDES FOR THE TREATMENT OF A DISEASE OR CONDITION MEDIATED BY FILAGGRIN OR COLLAGEN DEFICIENCYSeptember 2021August 2024Allow3500NoNo
17433204CYAN COLORED CURABLE COMPOSITIONAugust 2021March 2025Abandon4301NoNo
17432838PROTEIN AND/OR PEPTIDE MODIFICATION MOLECULEAugust 2021March 2025Allow4311NoNo
17407146LUMINESCENT PARTICLE AND COMPOUNDAugust 2021August 2024Allow3600NoNo
17396312AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORSAugust 2021January 2025Abandon4210NoNo
174287303-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORSAugust 2021October 2024Allow3810NoNo
17421336STEROID COMPOUND, AND USE THEREOF AND PREPARATION METHOD THEREFORJuly 2021April 2025Allow4511NoNo
17418858GEL COMPOSITION WITH AN ANAESTHETIC EFFECT OF SHORT AND LONG TERM DURATIONJune 2021February 2025Allow4411NoNo
17418019N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASESJune 2021September 2024Allow3910YesNo
17415899CARBONIC ANHYDRASE INHIBITORS AND ANTIBIOTICS AGAINST MULTIDRUG RESISTANT BACTERIAJune 2021March 2025Allow4521YesNo
17311964BI-FUNCTIONAL NANOHYBRIDSJune 2021May 2025Abandon4702NoNo
17311433ANTIBACTERIAL COMPOUNDS AND USES THEREOFJune 2021March 2025Allow4611NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VAJDA, KRISTIN ANN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
91.2%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
15
Allowed After Appeal Filing
5
(33.3%)
Not Allowed After Appeal Filing
10
(66.7%)
Filing Benefit Percentile
47.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner VAJDA, KRISTIN ANN - Prosecution Strategy Guide

Executive Summary

Examiner VAJDA, KRISTIN ANN works in Art Unit 1622 and has examined 1,000 patent applications in our dataset. With an allowance rate of 88.4%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 17 months.

Allowance Patterns

Examiner VAJDA, KRISTIN ANN's allowance rate of 88.4% places them in the 65% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by VAJDA, KRISTIN ANN receive 1.00 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by VAJDA, KRISTIN ANN is 17 months. This places the examiner in the 96% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +11.1% benefit to allowance rate for applications examined by VAJDA, KRISTIN ANN. This interview benefit is in the 49% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 42.3% of applications are subsequently allowed. This success rate is in the 93% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 80.3% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 91.7% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 72.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 52.5% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.1% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.3% of allowed cases (in the 67% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.